A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS … BS Skikne, MR Ward, A Nasser, L Aukerman, G Garcia-Manero Journal of Clinical Oncology 26 (15_suppl), 7091-7091, 2008 | 3 | 2008 |
Chemotherapy for non-small cell lung cancer in the intensive care unit A Nasser, M Hartwick, K Kyeremanteng, P Wheatley-Price Cancer Treatment and Research Communications 26, 100294, 2021 | 2 | 2021 |
Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis M Bradbury, D Akurang, A Nasser, S Moore, HS Sekhon, ... Cancer Treatment and Research Communications 32, 100570, 2022 | 1 | 2022 |
Global Psychopharmacology Overuse A Nasser, R Yurk Int Health Cert, 2012 | | 2012 |
Involvement of Palliative Care in Malignant Pleural Mesothelioma Patients and Associations with Survival and End-of-Life Outcomes A Baird, A Nasser, P Tanuseputro, C Webber, P Wheatley-Price, C Munro Current Oncology 31 (2), 1028-1034, 2024 | | 2024 |
Maternal Care Efficiency in Developing Countries A Nasser | | |
Mixed pancreatic acinar cell-ductal adenocarcinoma: Complexities in diagnosis and treatment A Nasser, CL Forse, C Walsh, T Moyana, R Goel Current Problems in Cancer: Case Reports 5, 100144, 2022 | 1 | 2022 |
Overfishing: economic policies in finite resource biological pools A Nasser Undergraduate Economic Review 9 (1), 9, 2013 | 4 | 2013 |
Paraneoplastic manifestations of salivary gland tumours: A case report and review A Nasser, B Purgina, S Laurie Oral Oncology 103, 104582, 2020 | 2 | 2020 |
Ral mediates activity‐dependent growth of postsynaptic membranes via recruitment of the exocyst RO Teodoro, G Pekkurnaz, A Nasser, ME Higashi‐Kovtun, M Balakireva, ... The EMBO journal 32 (14), 2039-2055, 2013 | 66 | 2013 |
Ready-to-use therapeutic foods A Nasser University of Western Ontario Medical Journal 83 (2), 26-27, 2014 | 1 | 2014 |
Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2-advanced breast cancer. R Patel, A Nasser Journal of Clinical Oncology 42 (16_suppl), e13066-e13066, 2024 | | 2024 |
Real-world prognostic model for malignant pleural mesothelioma. A Nasser, A Baird, MD Saint-Pierre, SA Laurie, P Wheatley-Price Journal of Clinical Oncology 39 (15_suppl), e20562-e20562, 2021 | 1 | 2021 |
Telehealth in rural Canada A Nasser, N Chen JPEN J Parenter Enteral Nutr 31 (3), 234-9, 2014 | 4* | 2014 |
Three decades of malignant pleural mesothelioma: an academic center experience A Nasser, A Baird, MD Saint-Pierre, K Amjadi, S Laurie, P Wheatley-Price Clinical Lung Cancer 22 (5), 441-448, 2021 | 2 | 2021 |
Using exponential decay to model survival curves in immunotherapy trials. TD Opperman, DJ Stewart, A Nasser Journal of Clinical Oncology 42 (16_suppl), e14698-e14698, 2024 | | 2024 |
UWOMJ A Chow, K Guidolin, M Drew, A Levit, D Darmawikarta, L Prufer, S Ahmed, ... | | |
Why do breast cancer patients visit the emergency department? S Kulkarni, A Nasser Journal of Clinical Oncology 33 (15_suppl), e12046-e12046, 2015 | | 2015 |